Loading…
Loading…
FNCH (Finch Therapeutics Group, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
FNCH does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FNCH and 80,000+ other tickers.
See exactly how FNCH's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FNCH and 80,000+ other tickers.
Finch Therapeutics is a microbiome technology company with a portfolio of intellectual property and microbiome assets. The company is now focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations after winding down development efforts.
Finch Therapeutics Group, Inc. (NASDAQ: FNCH - Get Free Report) dropped 2.7% during trading on Wednesday. The stock traded as low as $12.50 and last traded at $12.50. Approximately 283 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,590 shares. The stock had previously closed at $12.85.
Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Profitability This table compares Eloxx Pharmaceuticals and Finch Therapeutics Group's
Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Eloxx Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals"s revenue, earnings per share and
Earnings and Valuation This table compares Finch Therapeutics Group and ZIVO Bioscience"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75 million ($8.82) -1.53 ZIVO Bioscience $15,850.00 2,464.05 -$7.78 million ($2.18) -4.55 ZIVO Bioscience has higher revenue and earnings than
ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision that could significantly impact its share value, with a minimum award level already set. Nam Tai Property secured significant financing and sold a non-core property above appraisal value, indicating a potential closing of the gap between market price and fair value.